

Statement

To whom it may concern:

Product name: **One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)**

We, Getein Biotech, Inc., stated that as of April 14, 2022 in silico analysis and/or experimental analysis of the recombinant SARS-CoV-2 variants N protein has proved that the following SARS-CoV-2 variants have no impact on the test performance of the above products.

No.	Virus/Lineage	No.	Virus/Lineage
1	SARS-CoV-2	12	B.1.1.7 with E484K
2	B.1.1.7	13	B.1.525 (previously designated UK1188)
3	B.1.351 / B.1.429 / B.1.427	14	B.1.1.318
4	P.1	15	P.3
5	B.1.617/XD	16	AV.1
6	B.1.617.1	17	B.1.1.529 (Omicron)/BA.1/BA.1.1/XF
7	B.1.617.2	18	C.37
8	B.1.617.3	19	B.1.621
9	P.2	20	B.1.526
10	A.23.1 with E484K-1	21	BA.2/BA.3/BA.5/XE
11	A.23.1 with E484K-2	22	BA.4

After that, we will track the updates of SARS-CoV-2 variants on the following websites and databases on a **weekly basis**, conduct in silico analysis and test performance evaluation if there are new variants, update the statement and the evaluation after obtaining the results.

WHO website:

<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>

GISAID website:

<https://www.gisaid.org/hcov19-variants/>

UK website:

<https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data>

General manager:

Company: Getein Biotech, Inc. [Stamp]

April 14, 2022